A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway

详细信息    查看全文

• 作者：Jui-Ling Hsu ; Shih-Ping Liu ; Chia-Chung Lee…
• 关键词：Anthraquinone derivative ; LKB1 ; AMPK ; mTOR pathway ; Prostate cancer ; Selectivity ; PI3K/Akt inhibitors
• 刊名：Naunyn-Schmiedeberg's Archives of Pharmacology
• 出版年：2014
• 出版时间：October 2014
• 年：2014
• 卷：387
• 期：10
• 页码：979-990
• 全文大小：1,098 KB
• 参考文献：1. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541-551
  2. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramony Cajal S (2007) 4E-binding protein 1: a key molecular “funnel factor-in human cancer with clinical implications. Cancer Res 67:7551-555 CrossRef
  3. Asnaghi L, Bruno P, Priulla M, Nicolin A (2004) mTOR: a protein kinase switching between life and death. Pharmacol Res 50:545-49 CrossRef
  4. Baqi Y, Lee SY, Iqbal J, Ripphausen P, Lehr A, Scheiff AB, Zimmermann H, Bajorath J, Müller CE (2010) Development of potent and selective inhibitors of ecto-5-nucleotidase based on an anthraquinone scaffold. J Med Chem 53:2076-086 CrossRef
  5. Brenman JE (2007) AMPK/LKB1 signaling in epithelial cell polarity and cell division. Cell Cycle 6:2755-759 CrossRef
  6. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, Wen WC, Chen P, Guh JH (2010) Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol 79:162-71 CrossRef
  7. Coqueret O (2002) Linking cyclins to transcriptional control. Gene 299:35-5 CrossRef
  8. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-89 CrossRef
  9. Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, Zhang N, Musi N, DeFronzo RA, Liu F, Dong LQ (2011) APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol Endocrinol 25:1773-785 CrossRef
  10. Ding Y, Zhao L, Mei H, Zhang SL, Huang ZH, Duan YY, Ye P (2008) Exploration of emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur J Pharmacol 590:377-86 CrossRef
  11. Fruman DA, Edinger AL (2008) Cancer therapy: staying current with AMPK. Biochem J 412:e3–e5 CrossRef
  12. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM (1998) Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 53:467-74
  13. Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N (2008) LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res 68:55-3 CrossRef
  14. Hezel AF, Bardeesy N (2008) LKB1; linking cell structure and tumor suppression. Oncogene 27:6908-919 CrossRef
  15. Hsiao CJ, Li TK, Chan YL, Hsin LW, Liao CH, Lee CH, Lyu PC, Guh JH (2008) WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Biochem Pharmacol 75:847-56 CrossRef
  16. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-90 CrossRef
  17. Keith CT, Schreiber SL (1995) PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270:50-1 CrossRef
  18. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H (2010) Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 74:1822-826 CrossRef
  19. Kuznetsov JN, Leclerc GJ, Leclerc GM, Barredo JC (2011) AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther 10:437-47 CrossRef
  20. Lee CC, Huang KF, Lin PY, Huang FC, Chen CL, Chen TC, Guh JH, Lin JJ, Huang HS (2012) Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives. Eur J Med Chem 47:323-36 CrossRef
  21. Lo B, Strasser G, Sagolla M, Austin CD, Junttila M, Mellman I (2012) Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways. J Cell Biol 199:1117-130 CrossRef
  22. Marignani PA (2005) LKB1, the multitasking tumour suppressor kinase. J Clin Pathol 58:15-9 CrossRef
  23. Morton JP, Jamieson NB, Karim SA, Athineos D, Ridgway RA, Nixon C, McKay CJ, Carter R, Brunton VG, Frame MC, Ashworth A, Oien KA, Evans TR, Sansom OJ (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139:586-97 CrossRef
  24. Mukherjee P, Mulrooney TJ, Marsh J, Blair D, Chiles TC, Seyfried TN (2008) Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain. Mol Cancer 7:37 CrossRef
  25. Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B (2009) Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 15:1303-310 CrossRef
  26. Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR (2008) Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res 68:2223-232 CrossRef
  27. Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421-33 CrossRef
  28. Pópulo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13:1886-918 CrossRef
  29. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729-34 CrossRef
  30. Sanchez-Cespedes M (2011) The role of LKB1 in lung cancer. Familial Cancer 10:447-53 CrossRef
  31. Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxford) 196:65-0 CrossRef
  32. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101:3329-335 CrossRef
  33. Shi FH, Cheng YS, Dai DZ, Peng HJ, Cong XD, Dai Y (2013) Depressed calcium-handling proteins due to endoplasmic reticulum stress and apoptosis in the diabetic heart are attenuated by argirein. Naunyn Schmiedeberg's Arch Pharmacol 386:521-31 CrossRef
  34. Shor B, Gibbons JJ, Abraham RT, Yu K (2009) Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8:3831-837 CrossRef
  35. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-112 CrossRef
  36. Sun Y, Connors KE, Yang DQ (2007) AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol Cell Biochem 306:239-45 CrossRef
  37. Takahashi-Yanaga F, Sasaguri T (2008) GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 20:581-89 CrossRef
  38. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA (2011) Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle 10:1295-302 CrossRef
  39. Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY (2007) Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 27:7405-413 CrossRef
  40. Yecies JL, Manning BD (2011) mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berlin) 89:221-28 CrossRef
  41. Zhang F, Lazorchak AS, Liu D, Chen F, Su B (2012) Inhibition of the mTORC2 and chaperone pathways to treat leukemia. Blood 119:6080-088 CrossRef
  42. Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, Fang Q, Liu DD, Torres JM, Jia W, Lechleiter JD, Liu F, Dong LQ (2009) Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca²⁺/Ca²⁺/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 284:22426-2435 CrossRef
  
• 作者单位：Jui-Ling Hsu (1)
  Shih-Ping Liu (2)
  Chia-Chung Lee (3) (4)
  Lih-Ching Hsu (1)
  Yunn-Fang Ho (1)
  Hsu-Shan Huang (3) (4)
  Jih-Hwa Guh (1)
  
  1. School of Pharmacy, National Taiwan University, No. 1, Sect. 1, Jen-Ai Road, Taipei, 100, Taiwan
  2. Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
  3. School of Pharmacy, National Defense Medical Center, Taipei, Taiwan
  4. Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
  
• ISSN：1432-1912

文摘

Hormone-refractory metastatic prostate cancer (HRMPC), which is metastatic and resistant to hormone therapy, is an intractable problem in clinical treatment. Anthraquinone-based natural products and synthetic compounds have shown anticancer activity. However, cardiac toxicity is a major adverse reaction in these compounds. CC-36, a unique anthraquinone derivative, displayed higher antiproliferative activity in HRMPC than that in H9c2 cardiomyoblasts and normal prostate cells with the selectivity of five and twelve times, respectively. CC-36 caused G1 arrest of the cell cycle associated with an upregulation of p21 and downregulated levels of cyclin D1 and cyclin E expressions. Immunoprecipitation assay and Western blotting analysis showed that CC-36 triggered an increase of TSC1/TSC2 association and suppressed the phosphorylation of mammalian target of rapamycin (mTOR) (Ser2448) and p70 ribosomal protein S6 kinase (p70S6K) (Thr389), indicating the inhibition of both kinases-activities. CC-36 induced liver kinase B1 (LKB1) phosphorylation at Thr189, leading to LKB1 translocation from nucleus to cytosol for AMPKα phosphorylation (Thr172) and the kinase activation. The signaling pathway was validated using small interfering RNA (siRNA) technique with LKB1 knockdown. The combination treatment of MK2206 (a specific Akt inhibitor) with CC-36 showed a synergistic apoptosis in PC-3 cells indicating a potential combination strategy for LKB1 activators. Taken together, the data suggest that CC-36 displays anti-HRMPC activity through the activation of LKB1-AMPK pathway, leading to an inhibition of mTOR signaling and the induction of G1 arrest of the cell cycle. The combination use of Akt inhibitors with agents acting through LKB1-AMPK-mTOR pathway is a potential strategy for HRMPC treatment.